$28.86
▲ +1.8% Today
as of Aug 5, 16:45 ET
Last 30 days
Recent Press Releases & News
Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
ALZpath Broadens Strategic Agreement with Alamar Biosciences to Advance Clinical Diagnostics for Alzheimer's Disease
Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026
Overview
52-week range
$19
$27
100% of range
Avg surprise (last 0)
—
Avg reaction (last 1)
+1.3%
100% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Fri May 8, 2026 | Mar/2026 | $-1.74 | — | — | — | +1.3% | earnings |
| Mon Mar 31, 2025 | Mar 2025 | $-0.68 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 10, 2026 | Jun/2026 | AMC | -$0.36 | — |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Mar 2025 |
|---|---|---|---|
| Revenue | $26M | — | $13M |
| Cost of revenue | $12M | — | $7M |
| Gross profit | $14M | — | $6M |
| Operating income | $-12M | — | $-9M |
| Net income | $-21M | — | $-8M |
| EPS (diluted) | $-1.74 | — | $-0.68 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Mar 2025 |
|---|---|---|---|
| Cash & equivalents | $65M | $30M | — |
| Inventory | $40M | $38M | — |
| Total current assets | $141M | $95M | — |
| Total assets | $186M | $140M | — |
| Long-term debt | — | — | — |
| Total liabilities | $130M | $64M | — |
| Total equity | $-178M | $-159M | — |
Implied volatility — last 90 days
No IV snapshots yet for ALMR.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.